设为首页 电子邮箱 联系我们

本刊最新招聘信息请见“通知公告”!  本刊投稿系统试运行中,欢迎投稿!如投稿有问题,可直接将稿件发送至zgyy8888@163.com

 

主管单位:中华人民共和国   

国家卫生健康委员会

主办单位:中国医师协会
总编辑:
杨秋

副总编辑:魏永祥、张运、

罗毅、谭学瑞、唐来坤、

王喜艳

编辑部主任:杨秋

邮发代号:80-528
定价:20.00元
全年:240.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)

                  

过刊目录

2021 年第 9 期 第 16 卷

盐酸安罗替尼二线治疗老年小细胞肺癌的有效性和安全性观察

Effectiveness and safety of anlotinib hydrochloride second-line treatment on small cell lung cancer in elderly patients

作者:王宁军马银杰高业博薛鹏高音周磊朱世杰

英文作者:Wang Ningjun Ma Yinjie Gao Yebo Xue Peng Gao Yin Zhou Lei Zhu Shijie

单位:中国中医科学院望京医院肿瘤科,北京100102

英文单位:Department of Oncology Wangjing Hospital of China Academy of Chinese Medical Science Beijing 100102 China

关键词:小细胞肺癌;广泛期;盐酸安罗替尼;老年患者

英文关键词:Smallcelllungcancer;Extensivestage;Anlotinibhydrochloride;Elderlypatients

  • 摘要:
  • 目的 观察盐酸安罗替尼在老年小细胞肺癌患者中二线治疗的有效性和安全性。方法 选择20186月至20206月在中国中医科学院望京医院肿瘤科住院治疗的28例确诊为广泛期小细胞肺癌的老年患者为研究对象。在一线治疗进展后予以盐酸安罗替尼口服进行二线治疗。通过观察治疗后的客观有效率(ORR)、疾病控制率(DCR)及不良反应,评估盐酸安罗替尼在老年小细胞肺癌患者中二线治疗的有效性及安全性。结果 28例患者服用盐酸安罗替尼进行二线治疗后的ORR28.6%8/28),DCR60.7%17/28)。不良反应包括高血压、白细胞减少、凝血功能异常、肝肾功能异常、胃肠道反应、乏力、口腔黏膜炎、腹泻、蛋白尿等,以0~Ⅱ级为主,按需予以对症处理后缓解,严重不良反应发生率低。结论 盐酸安罗替尼在老年小细胞肺癌患者的二线治疗中效果较好,不良反应可控,可以考虑作为不能耐受化疗的老年小细胞肺癌患者的二线治疗选择。

  • Objective To observe the effectiveness and safety of anlotinib hydrochloride for second-line treatment on small cell lung cancer in elderly patients. Methods From June 2018 to June 2020, 28 elderly patients with extensive stage small cell lung cancer in Department of Oncology, Wangjing Hospital of China Academy of Chinese Medical Science were selected. They were treated with anlotinib hydrochloride orally for second-line therapy after first-line treatment progress. The effectiveness and safety of anlotinib hydrochloride orally for second-line therapy on elderly patients with small cell lung cancer were evaluated by observing the objective response rate(ORR), disease control rate(DCR) and adverse reactions. Results The ORR and DCR of the 28 patients were 28.6%8/28 and 60.7%17/28 respectively by oral anlotinib hydrochloride for second-line treatment. Adverse effects included hypertension, leucocytopenia, coagulation dysfunction, abnormal liver and kidney function, gastrointestinal reaction, fatigue, oral mucositis, diarrhea, proteinuria and so on. The adverse effects were mostly grade 0-, the patients were relieved after symptomatic treatment, and the incidence of serious adverse reactions was low. Conclusions Anlotinib hydrochloride has a good effect for second-line treatment on elderly patients with small cell lung cancer, and the adverse reactions are controllable. It can be considered as a second-line treatment option for elderly patients with small cell lung cancer who cannot tolerate chemotherapy.

copyright 《中国医药》杂志编辑部
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址:www.chinamedicinej.com 京ICP备2020043099号-3
本系统由北京博思汇文数字科技有限公司设计开发 技术服务电话:400-921-9838
当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。







安卓


苹果

关闭